(19)

(11)

EP 4 511 372 A1

(12)

(43) Date of publication: 26.02.2025 Bulletin 2025/09 (21) Application number: 23792376.8 (22) Date of filing: 17.04.2023

(51) International Patent Classification (IPC):  C07D 471/02(2006.01) C07D 401/14(2006.01) C07D 471/04(2006.01) C07D 401/06(2006.01) (52) Cooperative Patent Classification (CPC): C07D 471/04 (86) International application number: PCT/US2023/018809 (87) International publication number: WO 2023/205074 (26.10.2023 Gazette 2023/43)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 18.04.2022 US 202263332181 P (71) Applicant: Mirati Therapeutics, Inc. Princeton, New Jersey 08543 (US)	(72) Inventors: SCATTOLIN, Thomas San Diego, CA 92121 (US) GAN, Yonghong San Diego, CA 92121 (US) CHEN, Cheng San Diego, CA 92121 (US) CHEN, Chengsheng San Diego, CA 92121 (US) (74) Representative: Mewburn Ellis LLP  City Tower 40 Basinghall Street London EC2V 5DE London EC2V 5DE (GB)